MentionFox
Home › Executive changes › SpyGlass Pharma, Inc.
Leadership changes · SGP · SEC Form 8-K, Item 5.02

Leadership changes at SpyGlass Pharma, Inc. (2026)

Before you join, sell to or invest in SpyGlass Pharma, Inc.

MentionFox check on SpyGlass Pharma, Inc.: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/spyglass-pharma

Check SpyGlass Pharma, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about SpyGlass Pharma, Inc.?

Who joined and who left SpyGlass Pharma, Inc. (SGP)? 1 appointment reported on 2026-02-09, each cited to the company's own filing.

Habib Dable was appointed Director of SpyGlass Pharma, Inc. As of November 14, 2026, SpyGlass Pharma, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 9, 2026, naming 1 appointment (Form 8-K, February 9, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Gilde Healthcare Holding B.V. also filed stake reports on 2 other companies ↓

Sell to companies like SpyGlass Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-02-09

SpyGlass Pharma, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-09. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as SpyGlass Pharma, Inc. files it.

Also on the record for SpyGlass Pharma, Inc.

DateRecordFigureOur pageSource
February 17, 2026Stake report, Schedule 13D, by RA Capital Management, L.P.24.1% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G, by Srinivas Akkaraju6.3% of the class5%+ stakesSource
February 13, 2026Stake report, Schedule 13D, by Gilde Healthcare Holding B.V.6.57% of the class5%+ stakesSource
February 13, 2026Stake report, Schedule 13D, by New Enterprise Associates 17, L.P.22.2% of the class5%+ stakesSource
February 13, 2026Stake report, Schedule 13G, by SANDS FRANK M.7.8% of the class5%+ stakesSource
February 10, 2026Stake report, Schedule 13D, by Vensana Capital I GP, LLC9.9% of the class5%+ stakesSource
February 6, 2026IPO filing, Form 424B4$16 a shareIPO filingsSource
January 29, 2026IPO filing, Form S-1/A$15 to $17 a shareIPO filingsSource
January 16, 2026IPO filing, Form S-1—IPO filingsSource
June 5, 2025Form D, private offering$75M soldForm D pageSource

Selling to them or working with them? See who runs SpyGlass Pharma, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on SpyGlass Pharma, Inc. and the records around it.

SpyGlass Pharma, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on SpyGlass Pharma, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on SpyGlass Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on SpyGlass Pharma, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    11 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-09InDirector8-K, 2026-02-09

Who leads SpyGlass Pharma, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to SpyGlass Pharma, Inc.?

New leaders reset buying decisions — get the Full Report on SpyGlass Pharma, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch SpyGlass Pharma, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Director at SpyGlass Pharma, Inc., with the record behind each one.

Find candidates like Director at SpyGlass Pharma, Inc.

Every change, in the filing's words

Filed 2026-02-09 · 8-K

Appointed: Habib Dable, Director

Habib Dable was appointed to the board of directors of SpyGlass Pharma, Inc. (the "Company") on February 5, 2026 in connection with the Company's initial public offering (the "IPO").

Also stated in this filing

  • Mr. Dable will serve as a Class I director until a successor is duly elected and qualified or until an earlier resignation or removal.
  • Mr. Dable will serve as a member of the compensation committee of the board of directors of the Company.
  • Mr. Dable has served as an advisor at RA Capital Management, L.P., an investment manager, since April 2022.
  • Previously, Mr. Dable served as President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company, from December 2016 until its acquisition by Merck in November 2021.
  • Prior to joining Acceleron, Mr. Dable held roles of increasing responsibility at Bayer AG beginning in 1994, serving as the President of Pharmaceuticals for Bayer in the U.S. from October 2015 until December 2016.
  • From 2013 to 2015, Mr. Dable served as the Executive Vice President and Global Head of Specialty Medicine for Bayer HealthCare Pharmaceuticals, and from 2010 to 2012, he was the Vice President of Ophthalmology Global Launch Team Head for EYLEA.

Tools for this story

Each opens in a new tab, filled in for SpyGlass Pharma, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/spyglass-pharma
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined SpyGlass Pharma, Inc.? Leadership changes (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/spyglass-pharma